These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26957512)

  • 1. Prostate Cancer Prevention: Concepts and Clinical Trials.
    Hamilton Z; Parsons JK
    Curr Urol Rep; 2016 Apr; 17(4):35. PubMed ID: 26957512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer prevention: concepts and clinical recommendations.
    Silberstein JL; Parsons JK
    Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):300-6. PubMed ID: 20567257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies.
    Liss MA; Thompson IM
    Curr Opin Urol; 2018 Jan; 28(1):42-45. PubMed ID: 29095730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on prostate cancer chemoprevention.
    Lowe JF; Frazee LA
    Pharmacotherapy; 2006 Mar; 26(3):353-9. PubMed ID: 16503715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on chemoprevention for prostate cancer.
    Strope SA; Andriole GL
    Curr Opin Urol; 2010 May; 20(3):194-7. PubMed ID: 20216317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention strategies for prostate cancer.
    Schmitz-Dräger BJ; Lümmen G; Bismarck E; Fischer C
    Minerva Urol Nefrol; 2012 Dec; 64(4):225-31. PubMed ID: 23288209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
    Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
    Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutrition, physical activity, and lifestyle factors in prostate cancer prevention.
    Ballon-Landa E; Parsons JK
    Curr Opin Urol; 2018 Jan; 28(1):55-61. PubMed ID: 29049045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer.
    Finelli A; Trottier G; Lawrentschuk N; Sowerby R; Zlotta AR; Radomski L; Timilshina N; Evans A; van der Kwast TH; Toi A; Jewett MA; Trachtenberg J; Fleshner NE
    Eur Urol; 2011 Apr; 59(4):509-14. PubMed ID: 21211899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmaco and diet based prostate cancer prevention].
    Eisinger F; Cancel-Tassin G; Azzouzi AR; Gravis G; Rossi D; Cussenot O
    Bull Cancer; 2013 May; 100(5):497-507. PubMed ID: 23694994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of prostate cancer.
    Vemana G; Hamilton RJ; Andriole GL; Freedland SJ
    Annu Rev Med; 2014; 65():111-23. PubMed ID: 24188663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer chemoprevention.
    Sandhu GS; Nepple KG; Tanagho YS; Andriole GL
    Semin Oncol; 2013 Jun; 40(3):276-85. PubMed ID: 23806493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer prevention: past, present, and future.
    Fleshner N; Zlotta AR
    Cancer; 2007 Nov; 110(9):1889-99. PubMed ID: 17893870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of prostate cancer: myths and realities.
    Violette PD; Saad F
    J Am Board Fam Med; 2012; 25(1):111-9. PubMed ID: 22218632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS; Fleshner NE; Thompson IM
    Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III prostate cancer chemoprevention trials.
    Parnes HL; Brawley OW; Minasian LM; Ford LG
    Recent Results Cancer Res; 2014; 202():73-7. PubMed ID: 24531780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review.
    Wilt TJ; Macdonald R; Hagerty K; Schellhammer P; Tacklind J; Somerfield MR; Kramer BS
    BJU Int; 2010 Nov; 106(10):1444-51. PubMed ID: 20977593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Opportunities and risks of 5α reductase inhibitors in the medical management of Active surveillance for localized prostate cancer].
    Linares Espinos E; Carballido Rodriguez J
    Arch Esp Urol; 2014 Jun; 67(5):457-61. PubMed ID: 24914845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of pivotal studies for prostate cancer risk reduction, past and present.
    Andriole GL
    Urology; 2009 May; 73(5 Suppl):S36-43. PubMed ID: 19375625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer: a serious disease suitable for prevention.
    Fitzpatrick JM; Schulman C; Zlotta AR; Schröder FH
    BJU Int; 2009 Apr; 103(7):864-70. PubMed ID: 19302133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.